Adial Pharmaceuticals, Inc ADIL

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

ADIL hizo una agrupación de acciones (split inverso) de 1:25 el 6 de febrero de 2026: cada 25 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 30 sept

  Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

  Adial Pharmaceuticals granted 155,446 stock options to a new employee at an exercise price of $4.22 per share as an inducement to employment. The options vest over four years and have a ten-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4). Following its June 2026 acquisition of Azora Therapeutics, Adial has shifted focus to treating inflammatory diseases, with AT177 as its lead program for ulcerative colitis treatment, currently in IND-enabling studies with an IND filing planned for H1 2027.

  

• Benzinga 11 jun

  Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

  Adial Pharmaceuticals acquired Azora Therapeutics and secured up to $64 million in financing to advance AT177, a colon-targeted AhR agonist for ulcerative colitis treatment. The deal includes $32 million upfront and potential $32 million in milestone-based funding, with Phase 1 clinical trials planned for mid-2027. The company also appointed Wendy Young, Ph.D. to its Board of Directors.